Quotables
"Fooling around with alternating current is just a waste of time. Nobody will use it, ever."
Thomas Edison ; 1889
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 8183275 | Substituted imidazoles as bombesin receptor subtype-3 modulators Certain novel substituted imidazoles are ligands of the human bombesin receptor and, in particular, are selective ligands of the human bombesin receptor subtype-3 (BRS-3). They are therefore useful for the treatment, control, or prevention of diseases and disorders ... | 05/22/2012 |
| 8124637 | Anthra [1, 2-d]imidazole-6,11-dione derivatives, preparation method and application thereof A series of novel anthra[1,2-d]imidazole-6,11-dione derivatives, and the preparation method and application of said derivatives, wherein said application includes a pharmaceutical composition containing said derivatives for treating cancer, and said application invo... | 02/28/2012 |
| 8114898 | Compositions and methods for treating purpura Embodiments of the present invention are directed to compositions and methods for the treatment of purpura. Preferred compositions comprise an α adrenergic receptor agonist selected from selective α1 adrenergic receptor agonist, selective α2 | 02/14/2012 |
| 8008334 | Bis-heterocyclic imidazolyl compounds The patent application relates to new heterocyclic compounds of the general formula (I) in which R, R1, R2, R3, R4 and n have the definitions elucidated in more detail in the description, to a process for preparing them an... | 08/30/2011 |
| 7939555 | Method of preparing a pharmaceutical cream and minimizing imiquimod impurity formation Pharmaceutical formulations and methods including an immune response modifier (IRM) compound and an oleic acid component are provided where stability is improved by using oleic acid have low polar impurities such as peroxides. ... | 05/10/2011 |
| 7923463 | Methods for stabilizing imiquimod for two months, four months, and six months Pharmaceutical formulations and methods including an immune response modifier (IRM) compound and an oleic acid component are provided where stability is improved by using oleic acid have low polar impurities such as peroxides. ... | 04/12/2011 |
| 7906542 | Pharmaceutical compositions comprising polymorphic forms α, β, and γ of rifaximin Crystalline polymorphous forms of rifaximin (INN), referred to as rifaximin α and rifaximin β, and a poorly crystalline form referred to as rifaximin γ, useful in the production of medicaments containing rifaximin for oral and topical use and obtained by means of... | 03/15/2011 |
| 7906543 | Method of reducing imiquimod impurity formation Pharmaceutical formulations and methods including an immune response modifier (IRM) compound and an oleic acid component are provided where stability is improved by using oleic acid have low polar impurities such as peroxides. ... | 03/15/2011 |
| 7902245 | Methods for reducing imiquimod impurities for two months, four months, and six months Pharmaceutical formulations and methods including an immune response modifier (IRM) compound and an oleic acid component are provided where stability is improved by using oleic acid have low polar impurities such as peroxides. ... | 03/08/2011 |
| 7902243 | Methods for improving imiquimod availability at two months, four months and six months between refined and compendial Pharmaceutical formulations and methods including an immune response modifier (IRM) compound and an oleic acid component are provided where stability is improved by using oleic acid have low polar impurities such as peroxides. ... | 03/08/2011 |
| 7902246 | Methods for controlling formation of imiquimod impurities for two months, four months, and six months Pharmaceutical formulations and methods including an immune response modifier (IRM) compound and an oleic acid component are provided where stability is improved by using oleic acid have low polar impurities such as peroxides. ... | 03/08/2011 |
| 7902244 | Method of preparing a pharmaceutical cream and minimizing imiquimod impurity formation (at least four months storage) Pharmaceutical formulations and methods including an immune response modifier (IRM) compound and an oleic acid component are provided where stability is improved by using oleic acid have low polar impurities such as peroxides. ... | 03/08/2011 |
| 7902242 | Method of stabilizing imiquimod Pharmaceutical formulations and methods including an immune response modifier (IRM) compound and an oleic acid component are provided where stability is improved by using oleic acid have low polar impurities such as peroxides. ... | 03/08/2011 |
| 7884120 | 2,4,5-trisubstituted imidazoles and their use as anti-microbial agents The present invention provides therapeutically effective 2,4,5-trisubstituted imidazole compounds, methods of preparing the same, and compositions comprising the compounds alone or in combination with other agents. The present invention further provides for the use ... | 02/08/2011 |
| 7816388 | Biotin diaminoderivatives and their conjugates with macrocyclic chelating agents Formula (I) compounds are described: Formula (I) where the radicals are as defined in the description, processes for their preparation, and their uses for the preparation of conjugates with radionuclides for use in human and animal therapy and diagnostics, particula... | 10/19/2010 |
| 7772267 | Bicyclic modulators of androgen receptor function There are provided compounds according to formula I wherein the substitutents are as described herein. Further provided are methods of using such compounds for the treatment of nuclear hormone receptor-associated conditions... | 08/10/2010 |
| 7709518 | Compounds for inflammation and immune-related uses The invention relates to compounds of formula (I): or a pharmaceutically acceptable salt, solvate, clathrate, or prodrug thereof wherein X, Y, A, Z, L and n are defined herein. These compounds are u... | 05/04/2010 |
| 7655683 | Imidazolopyrazole derivatives useful as selective androgen receptor modulators The present invention is directed to novel imidazolopyrazole derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by the androgen receptor. ... | 02/02/2010 |
| 7618992 | Method of treating cancer by co-administration of anticancer agents The present invention relates to a method of treating cancer by co-administration of an effective amount of 1-(2-methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2-ylmethyl)-4,9-dihydro-1H-naphtho[2,3-d]imidazol-3-ium bromide and an effective amount of one or more antica... | 11/17/2009 |
| 7517897 | Derivatives of 6,7-dihydro-5h -imidazo[1,2-a] imidazole-3-sulfonic acid Derivatives of 6,7-dihydro-5H-imidazo[1,2-a]imidazole-3-sulfonic acid which exhibit good inhibitory effect upon the interaction of CAMs and Leukointegrins and are thus useful in the treatment of inflammatory disease. ... | 04/14/2009 |
| 7482372 | Hydantoins and related heterocycles as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme (TACE) The present application describes novel hydantoin derivatives of formula (I): or pharmaceutically acceptable salt or prodrug forms thereof, wherein A, B, R1, R2, R3, R4, R5 | 01/27/2009 |
| 7442717 | Substituted 2-aminoimidazoles, process for their preparation, their use as medicament or diagnostic aid Novel substituted 2-aminoimidazoles of formula I, process for their preparation, their use as medicament or diagnostic aid, and medicament containing them. The compounds of this type are useful in the prevention or treatment of various disorders and can be employed ... | 10/28/2008 |
| 7419995 | N-substituted benzimidazoyl c-Kit inhibitors and combinatorial benzimidazole library Compounds represented by Formula (I): or a pharmaceutically acceptable salt or N-oxide thereof, are useful in the treatment of tumors. Combinatorial libraries composed of compounds represented by Formula (I) or benzimidazol... | 09/02/2008 |
| 7407968 | Compounds Compounds of formula (I) wherein RF1, RF2, Z, R1, R2, Ar, X and Y are as defined in the specification as well as salts and pharmaceutical compositions including the compounds were prepared. These compounds are useful in th... | 08/05/2008 |
| 7405234 | Bicyclic modulators of androgen receptor function The invention provides compounds according to formula I wherein the substitutents are as described herein. Further provided are methods of using such compounds... | 07/29/2008 |
| 7399755 | Formulations comprising multiple dietary and endogenously made antioxidants and B-vitamins and use of same The invention is directed to formulations comprised of multiple dietary and endogenously made antioxidants and B-vitamins and the use of these formulations in preventing and treating coronary artery disease. ... | 07/15/2008 |
| 7371760 | Medicinal compositions containing aspirin A combination of 2-acetoxy-5-(α-cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine or a pharmaceutically acceptable salt thereof, and aspirin, which possess excellent inhibitory activity against platelet aggregation and thrombogenesis, and ... | 05/13/2008 |
| 7345090 | Galenical formulation The invention relates to compounds of the formula I where R1, R2, R3, R4 and R5 have the meanings given in claim 1. The compound is suitable in particular for use in sk... | 03/18/2008 |
| 7323463 | Combination of brimonidine and timolol for topical ophthalmic use Disclosed are pharmaceutical compositions comprising brimondine and timolol for topical ophthalmic delivery and a method of treatment comprising administering said composition when indicated for glaucoma and associated conditions such as elevated intraocular pressur... | 01/29/2008 |
| 7320976 | Combination of brimonidine and timolol for topical ophthalmic use Disclosed are pharmaceutical compositions comprising brimondine and timolol for topical ophthalmic delivery and a method of treatment comprising administering said composition when indicated for glaucoma and associated conditions such as elevated intraocular pressur... | 01/22/2008 |
| 7314940 | Jun kinase inhibitors The present invention provides novel compounds of formula I and their use in the inhibition of c-Jun N-terminal kinases. The present invention further provides the use of these compounds in medicine, in particula... | 01/01/2008 |
| 7285551 | Fused-ring compounds and use thereof as drugs The present invention provides a fused ring compound of the following formula [I] wherein each symbol is as defined in the specification, a pharmaceutically acceptable salt thereof, and a therapeutic agent for he... | 10/23/2007 |
| 7282503 | Fungicidal mixtures based on imidazole derivatives Disclosed are fungicidal mixtures containing a synergistically effective amount of A) a triazolopyrimidine of formula I, and B) imidazole derivatives of formula II, wherein X1 and X2 represent halogen and phenyl which can be substituted by halo... | 10/16/2007 |
| 7271289 | Biphenylcarboxylic amide derivatives as p38 kinase inhibitors Compounds of formula (I): or pharmaceutically acceptable derivatives thereof, and their use as pharmaceuticals, particularly as p38 kinase inhibitors. ... | 09/18/2007 |
| 7265135 | 2-oxy, 2-amino, and 2-thio-imidazole compounds The invention relates to novel 2-Oxy, 2-Amino, and 2-Thio-imidazole compounds of formula (I): wherein all variables are as herein defined, pharmaceutical compositions containing the compo... | 09/04/2007 |
| 7244703 | Pharmaceutical compositions and methods for peptide treatment Compositions and methods for treating a patient with a pharmaceutically active peptide that combines a pharmaceutically active peptide, a permeation enhancer, and a carrier, are disclosed. ... | 07/17/2007 |
| 7244746 | Imidazolyl derivatives as corticotropin releasing factor inhibitors The present invention relates to novel heterocyclic antagonists of Formula (I) and pharmaceutical compositions comprising said antagonists of the corticotropin releasing factor receptor (“CRF receptor”) usefu... | 07/17/2007 |
| 7241741 | Methods and compositions for the treatment of asthma and related disorders The present invention provides methods for the treatment of respiratory tract mucositis in individuals in need of such treatment, the method comprising the systemic administration to the individual of therapeutically effective amounts of at least one anti-fungal age... | 07/10/2007 |
| 7241788 | Cannabinoid receptor ligands and uses thereof Compounds of Formula (I) and (II) that act as cannabinoid receptor ligands and their uses in the treatment of diseases linked to the mediation of the cannabinoid receptors in animals are described herein ... | 07/10/2007 |
| 7238699 | Imidazolyl derivatives as corticotropin releasing factor inhibitors The present invention relates to novel heterocyclic antagonists of Formula (I) and pharmaceutical compositions comprising said antagonists of the corticotropin releasing factor receptor (“CRF receptor”) usefu... | 07/03/2007 |
